key: cord-0834205-wwx4nais
authors: Hashmi, Shahrukh K.; Murad, M. Hassan; Theel, Elitza S.
title: Testing for SARS-CoV-2: Health Policy Implications in Low- and Middle-Income Countries
date: 2020-10-15
journal: Mayo Clin Proc
DOI: 10.1016/j.mayocp.2020.10.007
sha: 6b111d9ae15fbaa87789922490ba176207991681
doc_id: 834205
cord_uid: wwx4nais

nan

The current pandemic due to the SARS-CoV-2 virus has paralyzed the global economy i and it is predicted that on average, each additional month of the continued pandemic would cost 2.5-3% of the global gross domestic product ii . A plausible end of the pandemic would be the development of population-level immunity (herd immunity) iii , which can be achieved when the majority of a given population develops immunity to SARS-CoV-2, either via infection/recovery or via vaccination. To know how far we are from this goal, and to establish other strategies to respond to the pandemic, accurate epidemiology data are needed. Unfortunately, current data remain limited. For example, the case fatality rate requires knowing the number of people infected (the denominator of the rate). The early reported case fatality rates were exaggerated and uninterpretable (e.g. rates in Italy and Germany were reported as >13% and was 3%, respectively iv ). The early case fatality rate and other epidemiologic indicators were dependent on testing patterns and the accuracy of testing.

In low-and middle-income countries (LMIC), where the majority of the world population resides, the challenge is more prominent. SARS-CoV-2 molecular diagnostic test (i.e., of reverse transcriptionpolymerase chain reaction [RT-PCR]) access per 1000 individuals was approximately 0.25 in Bangladesh and 4.90 in Iran v . In contrast, many non-LMIC countries, like the United Arab Emirates, have set up massive testing facilities with the capability of conducting tens of thousands RT-PCR tests daily vi . Other countries have implemented sero-epidemiological investigations (serosurveys). A clear understanding of the differences between molecular RT-PCR and serologic testing, as well as knowledge of the characteristics of a good screening test, are necessary for patient and country-level decision-making.

A positive RT-PCR test means that the person has an active or recent case of COVID-19. In contrast, depending on the serologic test used, a positive antibody test (Ig M, Ig G or total antibodies) indicates that the patient has developed an immune response to the virus. Importantly, it does not necessarily indicate when the patient was infected -it may have occurred recently and they may still potentially be shedding live, infectious virus, or they may have been infected at some point in the past and are no longer infectious. There are multiple limitations of these tests. Most notably, for RT-PCR, while falsepositive results are rare, the sensitivity of these tests is impacted by the quality of the collected specimen, when the specimen was collected relative to symptom onset, and the quality of the test itself.

For serologic testing, false-negative results may occur if the sample is collected before the development of an immune response, if the individual is immunosuppressed, or in some cases, if the individual had mild or asymptomatic disease. False-positive antibody test results may also occur, which is why careful validation/verification of serologic tests is needed to fully understand their performance characteristics.

Data from the related Severe Acute Respiratory Syndrome (SARS) coronavirus indicate that the presence of antibodies may confer protective immunity for approximately 2 years; however, we do not yet know if this is true for SARS-CoV-2. Despite this, early on in the pandemic, some countries considered provision of immunity cards for SARS-CoV-2.

The current pandemic has revealed significant concerns associated with the quality of some commercially available serologic tests. Many countries including the United Kingdom, Turkey, and the Czech Republic have reported that the imported serologic tests were flawed during the internal validation studies. Moreover, there has been a huge influx of diagnostic test manufacturers who claim that their analytic validation studies show high sensitivity and specificity; however, for some assays, Use Authorization vii , however, ideally, sensitivity and specificity in mass testing should approach 100%. viii

Ideal choice. A good diagnostic test should have sufficient 1) pre-analytic validity (i.e., the test needs to conform to technical specifications that relate to the collection, handling, and storage of the specimen); 2) analytic validity (i.e., the test needs to measure the biomarker in an accurate manner concordant with a gold or reference standard in a laboratory setting), 3) clinical validity (i.e., the test needs to have diagnostic accuracy in classifying at risk population) and 4) clinical utility (i.e., the test needs to improve outcomes or decisions) ix .

Pragmatic Choice: Although the above mentioned criteria are necessary, in the real-world experience, implementing an ideal test with utility and validity characteristics may not always be possible. Additional criteria are subsequently needed to use a test in mass surveillance, such as cost-effectiveness, ease of use, and acceptability by the population. This may itself be affected by political, cultural and financial situations in each country.

J o u r n a l P r e -p r o o f workers need to be routinely tested for this infection at defined intervals? Many experts are currently recommending the RT-PCR screening of all asymptomatic healthcare personnel at defined intervals (frequency variable depending on the institutional policies), which may be a reasonable approach until further data is gathered, as a large study has indicated some utility of screening of healthcare workers x .

We provide a summary of the role of mass serologic testing to help understand key epidemiologic concepts such as local, regional and national transmission patterns, infection case fatality rates, and prevalence.

J o u r n a l P r e -p r o o f

The global macroeconomic impacts of COVID-19: Seven scenarios

Economic effects of coronavirus outbreak (COVID-19) on the world economy

Understanding herd immunity

Covid-19: Why Germany's case fatality rate seems so low

Methods Guide for Medical Test Reviews. Agency for Healthcare Research and Quality (US)

Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission